

A SYSTEMATIC REVIEW OF SPHERICAL AGGLOMERATION BY PARTICLE DESIGN OF DRUG FORMULATION

Velenti Chauhan^{1,2}, Hitesh Dalvadi^{3*}

1. Department of Pharmaceutics, Bhagwan Mahavir College of Pharmacy, Surat, Gujarat, India.
2. Department of Pharmaceutics, Faculty Pharmacy, Gujarat Technological University, Ahmedabad, Gujarat, India.
3. Department of Pharmaceutics, ROFEL Shri G. M. Bilakhia College of Pharmacy, Vapi, Gujarat, India.

ARTICLE INFO

Received:

18 Nov 2021

Received in revised form:

10 Feb 2022

Accepted:

16 Feb 2022

Available online:

28 Feb 2022

Keywords: Spherical agglomeration, Particle design, Crysyallo-co-agglomeration, Quasi emulsion solvent diffusion, Spherical crystallization

ABSTRACT

Particle design through various Spherical Agglomeration techniques used for many bulks and fine manufacturing industries with the latest temptation into pharmaceuticals with size modification. By this an addition of an immiscible bridging liquid to the formation of agglomerate crystals before deliquoring. The spherical agglomeration method can produce high-performance spherical shape particles in a single crystallization unit, even though it is quite challenging to control the particle size and shape. Multi-liquid phases play important role in dynamic balance among the intensity of adhesion, dispersion, and capillary action. The search terms spherical agglomeration, spherical crystallization, and drug formulation by spherical agglomeration were used to recognize peer-reviewed publications restricted to the English language in PubMed and Web of Science electronic databases issued from initiation until January 2022. A total of 606 publications were found, of which 24 met the inclusion criteria after all exclusion screening. The review showed that Spherical agglomeration techniques exhibited decreased crystallinity and design particle size and shape. The amount of bridging liquid along with the multi-liquid phase and various mechanical factors affects the characteristics of spherical particles. An *in vitro* and *in vivo* study depicts the effectiveness of spherical agglomeration techniques in many parameters like improved bioavailability and other compression parameters.

This is an **open-access** article distributed under the terms of the **Creative Commons Attribution-Non Commercial-Share Alike 4.0 License**, which allows others to remix, tweak, and build upon the work non commercially, as long as the author is credited and the new creations are licensed under the identical terms.

To Cite This Article: Chauhan V, Dalvadi H. A Systematic Review of Spherical Agglomeration by Particle Design of Drug Formulation. *Pharmacophore*. 2022;13(1):83-90. <https://doi.org/10.51847/zKvUsNENLq>

Introduction

Spherical agglomeration has been implemented for various high-dose drugs with poor compressibility and water solubility [1-3]. Spherical agglomeration is a precious technique in the formulation of micro-sponges, microspheres, micro balloons, nanospheres, and nanoparticles as a novel drug delivery system [4-7]. Spherical agglomeration is defined as “a novel approach for particle engineering by which agglomeration and crystallization can be implemented in simultaneously one step to convert crystals directly into compacted spherical form” [8-11]. Spherical agglomeration is a technique for the emergence of aggregates of crystals held together by liquid bridges [12-14]. Besides formulating spherical crystals it also enables co-precipitation of drugs and encapsulating polymers in the form of spherical particles [15-17].

In 1986, Kawashima *et al.* used the spherical crystallization technique for size enlargement of the drug in the field of pharmaceutical technology [12]. Spherical agglomeration can be defined by him as “An agglomeration process that converts crystalline drugs directly into a compacted spherical form for improving the flow ability, solubility, and compact ability” [18-20].

We endeavored to summarize the issued literature on existing Spherical agglomeration and its formulations for pharmaceuticals which describe the limitations of the Spherical agglomeration formulation and emphasize the potential of these methods in pharmacy practice.

Corresponding Author: Hitesh Dalvadi; Department of Pharmaceutics, ROFEL Shri G. M. Bilakhia College of Pharmacy, Vapi, Surat-396 191 Gujarat, India. E-mail: hpdalvadi@gmail.com.

Materials and Methods

This review was carried out according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.

Search Strategy

A structured search of PubMed and Web of Science identified the articles published till January 24, 2022. Search terms Spherical agglomeration, Spherical Crystallization, Drug formulation of agglomeration. Original research articles describing Spherical agglomeration for drug formulation were included. Each abstract was examined to determine eligibility for full-text review. A second reviewer resolved the discrepancies about article inclusion. Article abstracts were screened, and those included were subjected to full-text review.

Study Selection

The study selection was conducted by one of the coauthors individually (VC) with any disagreement being resolved by consensus or a second author (HD) acting as a judge. One review author (VC) conducted the literature survey in the databases separately appraised and extracted the probable titles and abstracts of the articles for inclusion; however, the final selection, inclusion, and exclusion of articles for systematic review were performed after consulting all co-authors. Studies using review articles, book chapters, meta-analyses, conference proceedings, editorials/letters, patents, and case reports were excluded.

Data Extraction

Data from included studies were extracted and summarized separately by one of the authors (VC). **Table 1** summarizes the following information about the studies: (a) Spherical agglomeration preparation methods; (b) Objectives of study; (c) types of substances used in techniques and Results.

Data Analysis

The data is presented as a portrayal. It was not possible to cache data or undertake a meta-analysis due to its heterogeneity.

Results and Discussion

Search Result

A flow diagram shows the search and Selected criteria used for the systematic review in **Figure 1**. A total of 79 citations were identified, and 34 studies met our inclusion touchstone. Abstracted details provided information about the objective(s) of the review; the “Spherical agglomeration” and “drug formulation” the results. We tabulated the studies in obedience to the substrate used; though, studies can be tabulated using alternative criteria.




Figure 1. Structured literature search on Spherical Agglomeration technologies

Included Article Characteristics and Quality Evaluation

After exclusion screening total of 24 citations was screened out from the summary of all methods described in **Table 1**.

Table 1. Spherical Agglomeration- Summary of the literature survey met with inclusion criteria

Sr. No.	Technology	Objective(s)	material composition
1	Crystallo-co Agglomeration Methods	A) The preparation, optimization, and evaluation of a new spherical agglomeration technique for glimepiride as a model of poorly soluble drugs [21].	Starlac/PVP, ethylcellulose 10 cps, HPMC, Polyethylene glycol 6000, polyvinylpyrrolidone K30 talc fine powder Dichloromethane, Tween 80
		B) To develop directly compressible, high-strength extended-release spherical agglomerates technique, crushing strength, and low friability [22].	
		C) Improving the solubility and dissolution of cilostazol [23].	
		D) Improved flow property and mechanical properties of Racecadotril, a poorly water-soluble anti-diarrheal agent [24].	
		E) Improved micromeritic and mechanical properties, solubility, and dissolution of Secnidazole [25].	
2	Quasi emulsion solvent diffusion method	A) Improve flow properties like higher bulk density, and compressibility, also improve the dissolution rate [26].	Methanol, Ethanol, Dichloromethane, Acetone, Isopropyl Alcohol, DMF, DMSO, HPMC K15M, Ethyl acetate, Dichloromethane, Chloroform, hexane, ethanol
		B) The improved powder properties and dissolution performance of the API by SC [27].	
		C) Improved micromeritic properties compared to the plain drug suggested its suitability for direct compression [28].	
		D) The problems Solved related to solubility, dissolution rate, bioavailability, flowability, and compressibility of the drug [29].	
		E) Improved properties for direct compression, the shape of the particle, and enhanced fragmentation during the compaction, also increased tensile strength and reduced elastic recovery of the compacts [30].	
3	Spherical crystallization method or solvent change method	A) Improved micromeritic and dissolution properties, in equivalence to the pure drug, high-speed compression, and enough stability under accelerated conditions at least for 1 month [31].	Dichloromethane, acetone, HPC, hydrophilic polymer, Eudragit RS 100, Eudragit RL 100, Eudragit L 100, dichloromethane (DCM), potassium dihydrogen phosphate and sodium hydroxide
		B) The objectives of this study were to prepare sustained release SAs of mefenamic acid using polymethacrylates by a spherical crystallization method [32].	
		C) Spherical crystallization mechanism to obtain agglomerates with improved physicochemical properties [33].	
		D) Sustained release matrix pellets were successfully prepared by SC methods [34].	
		E) Directly compressible Naproxen prepared by spherical crystallization which produces microcrystalline forms exhibiting poor micromeritic properties and poor aqueous solubility shows an increase in the bioavailability [35].	
4	Spherical Agglomeration	A) Developed lactose monohydrate solution for spray-drying to improve the aerosolization performance of dry powder inhalers [36].	Cross Povidone, Pregelatinized starch, Croscarmellose sodium, Cross povidone XL, Avicel pH 102, Starlac, mannitol, maize starch, Aerosil 200, PVP K30, L-HPC, Carbon tetrachloride, hexane, octanol, toluene, polyethylene glycol, cross-povidone, starch, cross Carmellose sodium, HPMC, ethylcellulose
		B) Enhance dissolution of poorly soluble drugs; enhancing its rate of release from tablet formulation prepared this technique [37].	
		C) Improved micromeritic properties, thus obviating the need for further processing by granulation and agglomeration [38].	
		D) KSR-592 b-form with lactose was developed to enhance the inhalation properties of DPI formulations via particle designing used in the Jethaler [39].	
		E) Formulate fast-disintegrating pellets by direct palletization in a rotary processor [40].	
		F) Improve the flowability and compression properties of propyphenazone [41].	
		G) Improve their powder processing, and micro-encapsulation, by agglomeration, sustained-release gelling microcapsules of CP prolong the pharmacological effect [42].	
		H) The particle design of the powders masked the bitterness without reducing its bioavailability using this one continuous process of agglomeration and microencapsulation [43].	

*Methods of Spherical Crystallization**Crystallo-Co-Agglomeration (CCA) Technique*

Crystallo-Co-Agglomeration technique is one of the novel particle designing methods that could be an efficient process to get a better of the mentioned limitation of spherical agglomeration [44]. The spherical agglomeration technique is restricted to only large dose drugs which having poor water solubility because excipients like disintegrating agents and diluents are hydrophilic hence the incorporation of these types of excipients in the agglomerates with the help of bridging liquid is difficult [45]. It is the modified spherical agglomeration technique used for Particle designing and size enlargement of all lower and higher doses, poor Soluble and Compressible drugs, and also the combination of the drug with or without diluents [46]. Steps for the preparation of agglomerate through the Crystallo-co-agglomeration technique shows in **Figure 2**. In this technique, agglomerates are produced via a single step; recently it is employed to enhance micromeritic, compression, and mechanical properties in the design of a multiple-unit particulate drug delivery system. By using this method, the drug is directly crystallized and agglomerated in combination with another drug and excipients with the use of an organic bridging liquid [47].




Figure 2. Crystallo-co-agglomeration technique

Advantages of Crystallo-co-Agglomeration [48-50]

- Less unit operation is required.
- Its processing cost is very economic.
- Spherical agglomerates are formed in a single step.
- The whole procedure is handled by a single person, so less manpower is required [51].
- As it is a single-step procedure and carried out in a closed and contamination-free environment proper GMP is followed [52].
- The spherical agglomerates obtained by this procedure are further utilized for direct compression of tablets and in the design of a multiple-unit particulate drug delivery system [53].

Limitation [54-56]

- It is very difficult to reproduce the same result due to the presence of many formulations and process variables.
- The drug combination which has the same physicochemical properties cause problem in simultaneous crystallization of drug combination at the same solvent pH and temperature condition [57].
- It is difficult to scale up the filtration and drying process used in crystallo-co-agglomeration [58].
- The use of organic solvent cannot be avoided [59].
- Due to more volume of external phase drug loss is increased [60].
- More power requirement because of increasing resistance for mixing of content due to more external phase volume [61].
- Adding of disintegrant or super disintegrant is difficult because of aq. the phase has been considered an external phase [62].

Quasi Emulsion Solvent Diffusion Technique

Preparation of Spherical agglomerate by Quasi Emulsion Diffusion technique presented in **Figure 3**. APIs are dissolved in a Good Solvent(GS) and afterward dispersed in a Poor (bad)Solvent(PS), quasi droplets are formed, despite the pure solvent being miscible [63, 64]. GS diffuses gradually out of the emulsion droplets because of the interfacial tension between the GS and PS, into the poor solvent and the poor solvent disperses into the droplet, by this drug crystallized inside of the droplet [65-67]. The crystallization of API happens by counter diffusion of GS and PS. The residual GS available in droplets serves as a bridging liquid to agglomerate which generates liquid bridges in between droplets and helps to form Spherical crystals [68, 69].




Figure 3. Quasi Emulsion Solvent Diffusion method

Spherical Agglomeration Technique

Spherical agglomeration is a technique in which three types of solvent are incorporated: Good Solvent (GS) in which drug is completely soluble; a Poor Solvent (PS) in which drug is not soluble except GS should be immiscible with PS and the third solvent Bridging Liquid (BL) which is incorporated in a small amount after the generation of crystals, to agglomerate them via generating the liquid bridges between the particles. The BL is incorporated with continuous agitation [70, 71]. **Figure 4** shows the preparation method of Spherical agglomerates.




Figure 4. Spherical agglomeration method

Conclusion

The present structured review on the topic explores the different methods of spherical agglomeration employed in pharmaceutical formulation and their potential applications in developing new particulate systems in a drug. From the literature, these techniques have been used to modify pharmaceutical processing, drug product performances, and bioavailability issues. Spherical agglomerates exhibited a decrease in their crystallinity and enhanced micromeritic properties. Quantity of bridging liquid, rate of agitation, and time of agitation influenced the mechanical and micromeritic properties of spherical agglomerates. An *in vitro* and *in vivo* study depicts the effectiveness of the spherical agglomeration technique in many parameters like improved bioavailability and other compression parameters.

Acknowledgments: The authors would like to acknowledge and thank for the support of the Library of Bhagwan Mahavir College of Pharmacy, Bhagwan Mahavir University.

Conflict of interest: None

Financial support: None

Ethics statement: None

References

1. Kumar AP. Designing of efavirenz spherical agglomerates to improve micromeritics, solubility, and dissolution. *Med Chem.* 2015;2(1):8-15.
2. Mazzotti M, Pawel MO, Byeongho A. Tuning the Particle Sizes in Spherical Agglomeration. *Cryst Growth Des.* 2018;18(10):6257-65.
3. Chatterjee A, Gupta MM, Srivastava B. Spherical Crystallization: A technique use to reform Solubility and flow property of active pharmaceutical ingredients. *Int J Pharma Investig.* 2017;7(1):4-9.
4. Pitt K, Ramon P, Jonathan D, Litster JD. Particle design via Spherical agglomeration: A critical review of controlling parameters, rate processes and modelling. *Pow Tech.* 2017;11:52-74.
5. Deshkar SS, Borde GR, Thomas AB. Formulation of Cilostazol Spherical Agglomerates by Crystallo-co-Agglomeration technique and optimization using design of Experimentation. *Int J Pharma Investig.* 2017;7(4):164-73.
6. Peña R, Burcham CL, Jarmer DJ. Modeling and Optimization of Spherical Agglomeration in Suspension through a Coupled Population Balance Model. *Chem Eng Sci.* 2017;167:66-77.
7. Krishna KV, Chandra KB. Development, characterization, and evaluation of empagliflozin spherical agglomerates using spherical agglomeration technique. *J Pharm Innov.* 2018;7(3):202-7.
8. Chen CW, Hung LL, Kuan LY, Tu L. Effects of Scale-Up and Impeller Types on Spherical Agglomeration of Dimethyl Fumarate. *Ind Eng Chem Res.* 2021;60(30):11555-67.
9. Wei L, Jing Y, Shichao D, Estevao M. Preparation and Formation Mechanism of L-Valine Spherulites via Evaporation Crystallization. *Ind Eng Chem Res.* 2021;60(16):6048-58.
10. Cheng X, Zhang X, Huang X, Wang T, Hao H. Insight into the growth of ordered agglomerates based on oriented attachment. *J Mol Liq.* 2021;327:114844.
11. Chen M, Liu X, Yu C. Strategy of selecting solvent systems for spherical agglomeration by the Lifshitz-van der Waals acid-base approach. *Chem Eng Sci.* 2020;220:115613.
12. Cheng X, Li F, Luo L, Ding Z, Zeng L, Mao Y, et al. On the selection of wetting liquid for spherical agglomeration of cefotaxime sodium. *Pow Technol.* 2020;363:593-601.
13. Arjmandi-Tash O, Tew JD, Pitt K, Smith R, Litster JD. A new mathematical model for nucleation of spherical agglomerates by the immersion mechanism. *Chem Eng Sci.* 2019;4:100048.
14. Maghsoodi M. Role of solvents in improvement of dissolution rate of drugs: Crystal habit and crystal agglomeration. *Adv Pharm Bull.* 2015;5(1):13-8.
15. Thakur A, Thipparaboina R, Kumar D, Kodukula SG, Shastri NR. Crystal engineered albendazole with improved dissolution and material attributes. *Cryst Eng Comm.* 2016;18(9):1489-94.
16. Jitkar S, Thipparaboina R, Chavan RB. Spherical Agglomeration of Platy Crystals: Curious Case of Etodolac. *Cryst. Growth Des.* 2016;16(7):4034-42.
17. Chatterjee A, Gupta MM, Srivastava B. Spherical crystallization: A technique use to reform solubility and flow property of active pharmaceutical ingredients. *Int J Pharm Investig.* 2017;7(1):4-9.
18. Chen CW, Lee T. Round Granules of Dimethyl Fumarate by Three-in-One Intensified Process of Reaction, Crystallization, and Spherical Agglomeration in a Common Stirred Tank. *Org Process Res Dev.* 2017;21(9):1326-39.
19. Gyulai O, Aigner Z. On-line Observation of the Crystal Growth in the Case of the Non-Typical Spherical Crystallization Methods of Ambroxol Sulfate. *Pow Tech.* 2018;336:144-9.
20. Makar RR, Latif R, Hosni EA, El Gazayerly ON. A New Crystal Engineering Technique for Dissolution Enhancement of Poorly Soluble Drugs Combining Quasi-emulsion and Crystallo-co Agglomeration Methods. *Iran J Pharm Res.* 2020;19(2):219-35.
21. Dalvadi H, Parmar K, Yadav S. Spherical agglomeration to improve dissolution and micromeritic properties of an anticancer drug, Bicalutamide. *Drug Dev Ind Pharm.* 2019;45(6):968-80.
22. Chen H, Aburub A, Sun CC. Direct compression tablet containing 99% active ingredient-a tale of spherical crystallization. *J Pharm Sci.* 2019;108(4):1396-400.
23. Gaikwad VL, Jadhav NR, Pawar AP, Mahadik KR. Development of High-Strength Extended-Release Multiparticulate System by Crystallo-co-agglomeration Technique with Integration of Central Composite Design. *AAPS Pharm Sci Tech.* 2019;20(5):192-17.
24. Molina C, Kaialy W, Chen Q, Commandeur D, Nokhodchi A. Agglomerated novel spray-dried lactose-leucine tailored as a carrier to enhance the aerosolization performance of salbutamol sulfate from DPI formulations. *Drug Deliv Transl Res.* 2018;8(6):1769-80.
25. Deshkar SS, Borde GR, Kale RN, Waghmare BA, Thomas AB. Formulation of cilostazol spherical agglomerates by crystallo-co-agglomeration technique and optimization using design of experimentation. *Int J Pharm Investig.* 2017;7(4):164-73.
26. Makar RR, Latif R, Hosni EA, El Gazayerly ON. The Impact of Amorphisation and Spheronization Techniques on the Improved in Vitro & in Vivo Performance of Glimepiride Tablets. *Adv Pharm Bull.* 2017;7(4):557-67.
27. Fadke J, Desai J, Thakkar H. Formulation Development of Spherical Crystal Agglomerates of Itraconazole for Preparation of Directly Compressible Tablets with Enhanced Bioavailability. *AAPS Pharm Sci Tech.* 2015;16(6):1434-44.

28. Pandey S, Patil AT. Preparation, evaluation, and need of spherical crystallization in case of high-speed direct tableting. *Curr Drug Deliv.* 2014;11(2):179-90.
29. Garala KC, Patel JM, Dhingani AP, Dharamsi AT. Preparation and evaluation of agglomerated crystals by crystallo-co-agglomeration: an integrated approach of principal component analysis and Box-Behnken experimental design. *Int J Pharm.* 2013;452(1-2):135-56.
30. Raval MK, Sorathiya KR, Chauhan NP, Patel JM, Parikh RK, Sheth NR. Influence of polymers/excipients on development of agglomerated crystals of secnidazole by crystallo-co-agglomeration technique to improve processability. *Drug Dev Ind Pharm.* 2013;39(3):437-46.
31. Tapas A, Kawtikwar P, Sakarkar D. An improvement in physicochemical properties of carvedilol through spherically agglomerated solid dispersions with PVP K30. *Acta Pol Pharm.* 2012;69(2):299-308.
32. Ozyazici M, Sevgi F, Pekcetin C, Sarpas B, Sayin S. Sustained release spherical agglomerates of polymethacrylates containing mefenamic acid: in vitro release, micromeriticproperties, and histological studies. *Pharm Dev Technol.* 2012;17(4):483-893.
33. Patil SV, Pawar AP, Sahoo SK. Improved compressibility, flowability, dissolution, and bioavailability of pioglitazone hydrochloride by emulsion solvent diffusion with additives. *Die Pharmazie.* 2012;67(3):215-23.
34. Maghsoodi M. Effect of process variables on physicochemical properties of the agglomerates obtained by spherical crystallization technique. *Pharm Dev Technol.* 2011;16(5):474-82.
35. Pauli-Bruns A, Knop K, Lippold BC. Preparation of sustained-release matrix pellets by melt agglomeration in the fluidized bed: influence of formulation variables and modeling of agglomerate growth. *Eur J Pharm Biopharm.* 2010;74(3):503-12.
36. Nokhodchi A, Maghsoodi M. Preparation of spherical crystal agglomerates of naproxen containing disintegrant for direct tablet making by spherical crystallization technique. *AAPS Pharm Sci Tech.* 2008;9(1):54-9.
37. Ikegami K, Kawashima Y, Takeuchi H, Yamamoto H, Mimura K, Momose D, et al. A new agglomerated KSR-592 beta-form crystal system for dry powder inhalation formulation to improve inhalation performance in vitro and in vivo. *J Control Release.* 2003;88(1):23-33.
38. Kristensen J, Schaefer T, Kleinebudde P. Development of fast-disintegrating pellets in a rotary processor. *Drug Dev Ind Pharm.* 2002;28(10):1201-12.
39. Niwa T, Takeuchi H, Hino T, Itoh A, Kawashima Y, Kiuchi K. Preparation of agglomerated crystals for direct tableting and microencapsulation by the spherical crystallization technique with a continuous system. *Pharm Res.* 1994;11(4):478-84.
40. Ueda M, Nakamura Y, Makita H, Kawashima Y. One continuous process of agglomeration and microencapsulation for enoxacin. Preparation method and mechanism of microencapsulation. *J Microencapsul.* 1993;10(1):25-34.
41. Bausch A, Leuenberger H. Wet spherical agglomeration of proteins as a new method to prepare parenteral fast soluble dosage forms. *Int J Pharm.* 1994;101(1-2):63-70.
42. Bos A, zuiderweg I F. Size of agglomerates in batchwise suspension agglomeration. *Chem Eng Res Des.* 1987;65(2):187-94.
43. Chang Y, Menghui Y, Yiming M, Yanbo L. Design of the spherical agglomerate size in crystallization by developing a two-step bridging mechanism and the model. *AIChE J.* 2022;68(2):25-31.
44. Paradkar AR, Pawar AP. Crystallo-co-agglomeration: A novel particle engineering technique. *Asian J Pharm.* 2014;4(1).
45. Gupta MM. Crystallo-co-agglomeration of Valsartan for Improved Solubility and Powder Flowability. *Asian J Pharm.* 2018;12(03).
46. Wang JR, Bao J, Fan X, Dai W. pH-Switchable vitamin B9 gels for stoichiometry- controlled spherical co-crystallization. *Chem Commun.* 2016;52(3):13452-5.
47. Peña R, Oliva JA, Burcham CL, Jarmer DJ. Process Intensification through Continuous Spherical Crystallization Using an Oscillatory Flow Baffled Crystallizer (OFBC). *Cryst Growth Des.* 2017;17(9):4776-84.
48. Raval MK, Patel JM, Parikh RK, Sheth NR. Studies on influence of polymers and excipients on crystallization behavior of metformin Hcl to improve the manufacturability. *Particulate Sci Technol* 2017;32(5):431-44.
49. Zhu P, Wang L. Passive and Active Droplet Generation with Microfluidics: A Review. *Lab Chip.* 2017;17(1):34-75.
50. Peña R, Nagy ZK. Process Intensification through Continuous Spherical Crystallization Using a Two-Stage Mixed Suspension Mixed Product Removal (MSMPR) System. *Cryst Growth Des.* 2015;15(9):4225-36.
51. Huang S, Liu Y, Zhou Y, Li Q, Ren G, Jing Q. Exploring the effect of PVP on the spherical agglomeration process and micromeriticproperties of ascorbic acid. *J Powder Technol.* 2019;342:929-37.
52. Peña R, Oliva JA, Burcham CL, Jarmer DJ. Process Intensification through Continuous Spherical Crystallization Using an Oscillatory Flow Baffled Crystallizer (OFBC). *Cryst Growth Des.* 2017;17(9):4776-84.
53. Ravouru N, Penjuri SB, Damineni S, Muni RL, Poreddy SR. Preparation and in vitro evaluation of ibuprofen spherical agglomerates. *Turk J Pharm Sci.* 2018;15(1):7.
54. Ren F, Zhou Y, Liu, Y. A Mixed Solvent System for Preparation of Spherically Agglomerated Crystals of Ascorbic Acid. *Pharm Dev Technol.* 2017;22(6):818-26.
55. Chen H, Aburub A, Sun CC. Direct Compression Tablet Containing 99% Active Ingredient-A Tale of Spherical Crystallization. *J Pharm Sci.* 2019;108(4):1396-400.

56. Peña R, Jarmer DJ, Burcham CL. Further Understanding of Agglomeration Mechanisms in Spherical Crystallization Systems: Benzoic Acid Case Study. *Cryst Growth Des.* 2019;19(3):1668-79.
57. Lin PY, Lee HL, Chen CW. Effects of Baffle Configuration and Tank Size on Spherical Agglomerates of Dimethyl Fumarate in a Common Stirred Tank. *Int J Pharm.* 2015;495(2):886-94.
58. Wu S, Li K, Zhang T, Gong J. Size Control of Atorvastatin Calcium Particles Based on Spherical Agglomeration. *Chem Eng Technol.* 2015;38(6):1081-7.
59. Gyulai O, Szabó-Révész P, Aigner Z. Comparison Study of Different Spherical Crystallization Methods of Ambroxol Hydrochloride. *Cryst Growth Des.* 2017;17(10):5233-41.
60. Chen H, Wang C, Kang H, Zhi B. Microstructures and Pharmaceutical Properties of Ferulic Acid Agglomerates Prepared by Different Spherical Crystallization Methods. *Int J Pharm.* 2020;574:118914.
61. Oliva JA, Wu WL, Greene MR, Pal K, Nagy ZK. Continuous Spherical Crystallization of Lysozyme in an Oscillatory Baffled Crystallizer using Emulsion Solvent Diffusion in Droplets. *Cryst Growth Des.* 2020;20(2):934-47.
62. Tahara K, O'Mahony M, Myerson AS. Continuous spherical crystallization of albuterol sulfate with solvent recycle system. *Cryst Growth Des.* 2015;15(10):5149-56.
63. Li JS, Wu SW, Lu KT. Study on Preparation of Insensitive and Spherical High Bulk Density Nitroguanidine with Controllable Particle Size. *Propellants Explos Pyrotech.* 2016;41(2):312-20.
64. Peña R, Nagy ZK. Process Intensification through Continuous Spherical Crystallization Using a Two-Stage Mixed Suspension Mixed Product Removal (MSMPR) System. *Cryst Growth Des.* 2015;15(9):4225-36.
65. Sun M, Shichao D, Tang W, Jia L. Design of Spherical Crystallization for Drugs Based on Thermal-Induced Liquid-Liquid Phase Separation: Case Studies of Water-Insoluble Drugs. *Ind Eng Chem Res.* 2019;58(44):20401-11.
66. Chavda V, Maheshwari RK. Tailoring of ketoprofen particle morphology via novel crystallocoagglomeration technique to obtain a directly compressible material. *Asian J Pharm.* 2014;2(1):265-79.
67. Ochsenbein DR, Vetter T, Morari M, Mazzotti M. Agglomeration of Needle-like Crystals in Suspension II Modeling. *Cryst Growth Des.* 2015;15(9):4296-310.
68. Maghsoodi M, Yari Z. Effect of Drying Phase on the Agglomerates Prepared by Spherical Crystallization. *Iranian J Pharm Res.* 2015;14(2):51-7.
69. Borislav T, Christina V, Denitsa A, Jordan Y. Improvement of dissolution of poorly soluble glimepiride by loading on two types of mesoporous silica carriers. *J Solid State Chem.* 2018;271:253-9.
70. Lamešić D, Planinšek O, Lavrič Z. Spherical agglomerates of lactose with enhanced mechanical properties. *Int J Pharm.* 2017;516(1-2):247-57.
71. Patra CN, Swain S, Mahanty S, Panigrahi KC. Design and characterization of aceclofenac and paracetamol spherical crystals and their tableting properties. *Powder Technol.* 2015;274:446-54.